{"filing":{"accession_number":"0001178913-26-004329","cik":"0001553846","ticker":"RDHL","company_name":"RedHill Biopharma Ltd.","form":"6-K","filing_date":"2026-08-31","report_date":"2026-08-31","primary_document":"zk2636045.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1553846/000117891326004329/zk2636045.htm"},"events":[{"id":30479,"run_id":27930,"accession_number":"0001178913-26-004329","anchor_item_number":"EX-99.1","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"RedHill divested its 70% stake in Talicia to Apotex for $18 million upfront plus up to $35 million in milestone payments. This is a material disposition of a significant asset that generates immediate liquidity and represents a strategic repositioning of the company's commercial business. The transaction is explicitly described as \"a pivotal milestone\" and \"a major step in RedHill's strategic roadmap,\" directly affecting the company's asset base and capital structure.","company_name":"RedHill Biopharma Ltd.","ticker":"RDHL","filing_date":"2026-08-31","form":"6-K","submitted_at":null,"items":[{"id":33083,"accession_number":"0001178913-26-004329","item_number":"EX-99.1","item_title":"exhibit_99-1.htm","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"RedHill divested its 70% stake in Talicia to Apotex for $18 million upfront plus up to $35 million in milestone payments. This is a material disposition of a significant asset that generates immediate liquidity and represents a strategic repositioning of the company's commercial business. The transaction is explicitly described as \"a pivotal milestone\" and \"a major step in RedHill's strategic roadmap,\" directly affecting the company's asset base and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-31T11:05:06.603663+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33083,"accession_number":"0001178913-26-004329","item_number":"EX-99.1","item_title":"exhibit_99-1.htm","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"RedHill divested its 70% stake in Talicia to Apotex for $18 million upfront plus up to $35 million in milestone payments. This is a material disposition of a significant asset that generates immediate liquidity and represents a strategic repositioning of the company's commercial business. The transaction is explicitly described as \"a pivotal milestone\" and \"a major step in RedHill's strategic roadmap,\" directly affecting the company's asset base and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-31T11:05:06.603663+00:00","company_name":"RedHill Biopharma Ltd.","ticker":"RDHL","filing_date":"2026-08-31"}]}